Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 3/20 | 0.32 |
| ▸ | GLP1R | P43220 | 3/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3293189 | 0.88 | CAPN1 (0.39) | CAPN1NOD1DRD2CTSKGLP1R | |
| SCHEMBL3290839 | 0.85 | CTSK (0.35) | CTSK | |
| SCHEMBL3288375 | 0.83 | TDP1 (0.36) | CTSK | |
| SCHEMBL6889549 | 0.82 | CTSK (0.33) | CTSK | |
| SCHEMBL3287414 | 0.79 | CTSK (0.32) | CTSK | |
| SCHEMBL3289305 | 0.74 | CAPN1 (0.32) | CAPN1DRD2 | |
| SCHEMBL3293178 | 0.74 | DRD2 (0.35) | CAPN1NOD1DRD2CTSKDNM1 | |
| SCHEMBL3290851 | 0.71 | CTSK (0.37) | CTSK | |
| SCHEMBL4519161 | 0.71 | CTSK (0.32) | CTSK | |
| SCHEMBL3293190 | 0.69 | CA14 (0.36) | CAPN1DRD2CTSKHDAC8CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718157-B1 | Targeted lipid particles | BAKER TERENCE SEWARD | 2010-05-18 | — | — | US | disclosed |
| US-7531676-B2 | Lipids | CELLTECH R & D LIMITED (GB) | 2009-05-12 | — | — | US | disclosed |
| US-20060148761-A1 | Lipids | CELLTECH R & D LIMITED | 2006-07-06 | — | — | US | disclosed |
| US-20040024220-A1 | Lipids | CELLTECH R & D LIMITED | 2004-02-05 | — | — | US | disclosed |
| US-6583301-B1 | Bipolar; form complexes with polyanions; delivering bioactive substances such as nucleic acids to cells in vitro and in vivo | CELLTECH R & D LIMITED (GB) | 2003-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024220-A1 | Lipids | PHOSPHO1, FABP7, MBOAT7 | CAPN1 4378/4885NOD1 4433/4885SLC6A5 3050/4885 |
| US-20060148761-A1 | Lipids | PHOSPHO1, FABP7, MBOAT7 | CAPN1 4378/4885NOD1 4433/4885SLC6A5 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.